| Literature DB >> 29733339 |
Ronald McCarthy1, Carmel Martin-Fairey1, Dorothy K Sojka2, Erik D Herzog3, Emily S Jungheim4, Molly J Stout4, Justin C Fay5, Mala Mahendroo6, Jeff Reese7, Jennifer L Herington7, Erin J Plosa7, Elaine L Shelton7, Sarah K England1.
Abstract
Preterm birth affects approximately 1 out of every 10 births in the United States, leading to high rates of mortality and long-term negative health consequences. To investigate the mechanisms leading to preterm birth so as to develop prevention strategies, researchers have developed numerous mouse models of preterm birth. However, the lack of standard definitions for preterm birth in mice limits our field's ability to compare models and make inferences about preterm birth in humans. In this review, we discuss numerous mouse preterm birth models, propose guidelines for experiments and reporting, and suggest markers that can be used to assess whether pups are premature or mature. We argue that adoption of these recommendations will enhance the utility of mice as models for preterm birth.Entities:
Mesh:
Year: 2018 PMID: 29733339 PMCID: PMC6297318 DOI: 10.1093/biolre/ioy109
Source DB: PubMed Journal: Biol Reprod ISSN: 0006-3363 Impact factor: 4.285
Published preterm birth mouse models.
| Stimulant | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Type of model | Targeted mutation | Mouse strain | Expected gestational length (days) | Breeding method | Defined start of pregnancy | Treatment/ experimental manipulation | Route | Day of injection | Preterm delivery definition | Term delivery definition in paper | Pup survival | Reference |
| Infection | ||||||||||||
| N/A | CD-1 | 19–20 | ND | Vaginal plug; dpc not defined |
| IU/IP | 14.5 dpc | Within 48 h | ND | None | [ | |
| N/A | C3H/HeN x C3H/HeN C3H/HeN x B6D2F1 BALB/c x B6D2F1 | 19–20 | ND | Vaginal plug and spermatozoa in vaginal smear at 0.0 dpc | LPS serotype 055:B5 | IP - 50 or 100 μg/kg (one injection) Or 50 μg/kg (two injections) | 12, 15, or 17 dpc | <19 dpc | 19–20 dpc | None | [ | |
| N/A | CD-1 | ND | ND | Vaginal plug at 0.0 dpc | LPS serotypes 0111:B4, 055:B5, 0127:B8*, and 0128:B12 | IU 20 μg in 25 μl | 16 dpc | 36 h postinjection | 60 ± 15 h postinjection | LPS 0111:B4 none 055:B5 80% 0127:B8 95% 0128:B12 100% | [ | |
| TLR-4 mutant | CD-1 C3H/HeJ | 19–20 | Timed pregnant (supplier) | ND | LPS serotype L2280 (CD-1) L2880 and L4525 for TLR-4 mutant | IU 250 μg/mouse (Sigma) | 15 dpc | At least 1 pup born < 48 h after LPS admin | 19–20 dpc | None | [ | |
|
| 129S4/SvJae | ND | Vaginal plug at 0 dpc | No treatment, LPS serotype 055:B5 or RU486 | 250 μg LPS intravaginally SC 150 μg RU486 dissolved in DMSO | 15 dpc | Within 48 h postinjection | 20–21 dpc | ND | [ | ||
| N/A | CD-1 | 19–20 | ND | Vaginal plug, dpc not defined | TLR-2 ligand lipoteichoic acid, peptidoglycan, or TLR-3 ligand polyinosinic:cytidylic acid | IU and IP | 14.5 or 15.5 dpc | At least 1 pup born or in lower vagina <48 h after surgery | 19–20 dpc | None | [ | |
| N/A | C3H/HeNCrj X Crj: B6D2F1 | 19–20 | ND | Vaginal plug and spermatozoa in the vaginal smear at 0.0 dpc | Lipoteichoic acid | IP 12.5–75 mg/kg single dose or repeated doses at 3h intervals | 15 dpc 17 dpc | <19.0 dpc | 19–20 dpc | None with doses given on 15 dpc 100% viable with doses given on 17 dpc | [ | |
| N/A | C57BL/6 | 19.5 ± 0.5 | ND | ND | iE-DAP | IP 500, 750, or 1000 μg in 200 μl PBS | 14.5 dpc | Delivery within 24 h postinjection | ND | ND | [ | |
| N/A | CD-1 | ND | Timed pregnant (supplier) | ND | Heat-killed GBS | IP or IU 109 in 100 μl | 14.5 dpc | Within 48 h postinjection | ND | ND | [ | |
| N/A | C3H/HeN | 19–20 | ND | Vaginal plug at 0.0 dpc | Ureaplasmal outer membrane lipoprotein | IU 15 μg | 14.0 dpc | Within 48 h | ND | ND | [ | |
| N/A | BALB/c ( | 19–20 | Overnight | Vaginal plug at 0 dpc |
| 101 to 107 inclusion-forming units in 20 μl of 0.2 M sucrose–20 mM sodium phosphate (pH 7.2)–5 mM glutamic acid | 5 dpc | ND | 19.3 | Maternal cannibalism precluded evaluation | [ | |
| N/A | C3H/HeJ | 20 | Timed-pregnant (supplier) | ND |
| Urethral catheterization into urinary bladder | 7 dpc | On or before 18 dpc | ND | 53.6% | [ | |
| N/A | C57Bl/6J | 20.45 | ND | Vaginal plug at 0.0 dpc | W83 strain of | 108 CFU | 6 weeks before mating | 17–18.25 dpc | Delivery | ND | [ | |
| Faah–/–; Cnr–/– | ND | ∼19.8 | ND | Vaginal plug at 1.0 dpc | LPS 0111:B4 | IP 25 μg | 16.0 dpc | Before 19 dpc | ∼19.8 dpc | None | [ | |
| N/A | Kunming (derived from Swiss Webster) | ND | Overnight | Vaginal plug at 0.0 dpc | LPS serotype 0127 | IP 150 μg/kg | 15.5 dpc | 15.5–17 dpc | 18.0–20.0 dpc | 47% | [ | |
| N/A | CD-1 | 19–20 | Overnight | Vaginal plug at 0.0 dpc | LPS serotype 0111 | IU 10 μg | 16.0 dpc | 12.7 ± 7 h | ND | 14.6 ± 31% viable, but included deliveries 25–37 h after LPS | [ | |
| N/A | C57BL/6 | 19.5 ± 0.5 | Overnight | Vaginal plug at 0.5 dpc | LPS | IP 0.5 μg | 16.5 dpc | Before 18.0 dpc | ND | 2.3 fetuses per dam, may include term deliveries | [ | |
| N/A | C57BL/6 | 19.5 ± 0.5 | ND | Vaginal plug at 0.5 dpc | LPS serotype 0111:B4 | IA 100 ng/sac | 16.5 dpc | Before 18.0 dpc | ND | ND | [ | |
| Uterine-specific p53 knockout | FVB/129 | ND C57BL/6-129 | Overnight | Vaginal plug at 1.0 dpc | LPS | IP 10 μg/ml | 16.0 dpc | Before 19 dpc | ND | 28% w/o LPS; 0% with LPS | [ | |
| Inflammation | ||||||||||||
| N/A | C3H/Hel | 20–21 | Timed pregnant (supplier) | ND | Interleukin-1 | SC | 15–17 dpc | Within 24 h | 20–22 dpc | ND | [ | |
| N/A | C57BL/6 | 19.5 ± 0.5 | Overnight | Vaginal plug at 0.5 dpc | High-mobility group box-1 | IA 9 ng | 14.5 dpc | 17.35 dpc | 19.5 ± 0.5 dpc | ∼85.4% viability; 60.9 ± 11.7% pup death by 1 week of age | [ | |
| Cesarean | ||||||||||||
| N/A | CD-1 | 20 | Overnight | Vaginal plug at 1.0 dpc | Cesarean | NA | NA | On 18 or 19 dpc | 20 dpc | 0% (18 dpc) 87.8% (19 dpc) | [ | |
| N/A | CD-1 | 19–20 | Timed pregnant (supplier) | ND | Cesarean | NA | NA | 1 or 2 days before term | Delivery | 100% | [ | |
| PPROM | ||||||||||||
| N/A | C57BL/6 | 19.5 ± 0.5 | Pair mated (5 h) | ND | Fetal fibronectin | Between fetal membranes and uterine lining (100–200 μg/ml) | 17.0 dpc | <18.5 dpc | 19 dpc | 20% | [ | |
| Biglycan and Decorin double knockout | C3H | 19.5 | Overnight | Vaginal plug at 0.0 dpc | NA | NA | NA | Before 18.0 dpc | 19.5 dpc | 0% | [ | |
| Early progesterone withdrawal | ||||||||||||
| N/A | C3H/HeN | 19–20 | Overnight | Vaginal plug at 1.0 dpc | Mifepristone (RU486) | SC 50–250 μg | 12–14 dpc | Within 18 h | 19–20 dpc | 100% | [ | |
| Prostaglandins | ||||||||||||
| N/A | C3H/HeN | 19–20 | Timed Pregnant (supplier) | ND | Prostaglandin F2α | IP 20 μg | 16 dpc | Within 24 h | <18 dpc | ND | [ | |
| 15-hydroxy- prostaglandin dehydrogenase hypomorph | C57BL/6-129/SvJ | ∼19.3 | ND | Vaginal plug, dpc not defined | NA | NA | NA | Shorter gestation than control | ∼19.3 dpc | Equivalent to term | [ | |
| Uterine quiescence | ||||||||||||
| N/A | CD-1 | 19 | Timed pregnant (supplier) | ND | Tunicamycin | IP 0–1 mg/kg | 15 dpc | 18–32 h postinjection | 19 dpc | Nonviable neonates at 16 and 17 dpc | [ | |
| Endocannabinoid signaling | ||||||||||||
| CB1 knockout | C57BL/6J/129 | ∼20.1 | Overnight | Vaginal plug at 1.0 dpc | NA | NA | NA | Before ∼19.5 dpc | ∼20.1 dpc | Yes | [ | |
| Hyperhomocysteinemia | ||||||||||||
| CBS knockout | C57BL/6J | 20.0 ± 0.2 | Overnight | Vaginal plug at 0.5 dpc | NA | NA | NA | At 16.6 ± 0.1 dpc | 20.0 ± 0.2 dpc | Yes | [ | |
| Environmental effects | ||||||||||||
| N/A | C57BL/6 | 19.5 ± 0.5 | Overnight | Vaginal plug at 0.5 dpc | 2,3,7,8-tetrachlo- rodibenzo-p-dioxin (dioxin) | Mother was gavaged 10 μg/kg; no exposure as adult | In utero at 15.5 dpc, none as adult | 24 h before term | 20 dpc | Pups born preterm appeared viable at birth, died within 24 h Pups born at term survived | [ | |
| N/A | BL6C3F1 | 20.3 ± 0.2 | Two days | First day of pairing defined as 0.0 dpc | Cigarette smoke diluted 90% | Inhalation | 2–18 dpc | At 19.6 ± 0.2 dpc | 20.3 ± 0.2 dpc | Yes | [ | |
| Other | ||||||||||||
| N/A | CD-1 | 19–20 | Overnight | Vaginal plug at 0 dpc | L-arginine analog NG-nitro-L-arginine methyl ester (L-NAME) | SC 0 (vehicle), 40, 70, or 100 mg L-NAME/kg in 10 ml/kg body weight | 15.5 dpc and 16 dpc | Before 18 dpc | 18–19.5 dpc | Maternal cannibalism precluded evaluation | [ | |
| N/A | CD-1 | 19–20 | Overnight | Vaginal plug at 0 dpc | Methylene Blue | SC 5, 30, 50, 60 or 85 mg/kg in 5 ml/kgb | 15.5 dpc and 16 dpc | Before 18 dpc | 18–19.5 | Appeared viable but maternal cannibalism precluded evaluation | [ | |
| N/A | ICR (CD-1) | 19–20 | Overnight | Vaginal plug at 0.5 dpc | Surfactant protein (SP)-A | IA 3 μg in 50 μl per sac | 15 dpc | ND | 19 dpc | ND | [ | |
| N/A | BALB/C | 20.2 ± 0.1 | Overnight | Vaginal plug at 0 dpc | Neuromedin B | IP 30, 90, or 150 μg/kg of NMB | 18 dpc and 19 dpc at 1400 and 1800 h | ND | ND | ND | [ | |
| N/A | C57Bl/6J | 19.5 ± 0.5 | ND | Vaginal plug at 1 dpc | Alcohol | Intra-gastric 6 g/kg | 17 dpc or 18 dpc | 18.9 ± 0.1 dpc 19.5 ± 0.2 dpc | 20.1 ± 0.1 | ND | [ | |
aAs discussed by author or determined by [16]
bdpc, days postcoital
cIA, intraamniotic; IP, intraperitoneal; IU, intruterine; SC, subcutaneous
dincludes term deliveries
NA, not applicable
ND, not discussed
LPS, Lipopolysaccharide
Figure 1.Skin permeability as a marker of maturity. In C57BL/6 mice, dye permeated mice at 17.0 dpc. By 18.0 dpc, dye was excluded on the dorsal side, but the pup remained blue on the ventral side. By 19 dpc, the skin was impermeable and faint blue stain was only noted on the ventral side. (Please see the online version for the color figure.)
Figure 2.Skin histologic changes during gestation. In whole mount, the skin of 17 dpc CD-1 fetuses appeared more translucent (A) than that of 19 dpc fetuses (C). H&E-stained sections of dorsal skin from 17 dpc fetuses had thinner epidermal (E) and dermal papillary (DP) layers and contained fewer hair follicles (asterisks) than H&E-stained sections of skin from 19 dpc fetuses (B and D). (Please see the online version for the color figure.)
Figure 3.Lung morphometry as a marker of lung maturity. H&E stained lungs from 17 and 19 dpc CD-1 mouse fetuses (A, B). Lung morphometry measurements indicated that, compared to 17 dpc lungs, 19 dpc lungs contained more airspaces (C), had larger airspace volume density (airspace area divided by total lung area) (D), and had larger airspace diameter (E). However, airspace perimeter was similar in the two groups (F). n = 6 for both 17 and 19 dpc; *P-values, calculated by t-test; error bars represent SEM. (Please see the online version for the color figure.)
Figure 4.Gene expression as a marker of lung maturation. RNA isolated from pups of the indicated gestational ages was reverse transcribed to produce cDNA (SuperScript VILO kit; Invitrogen), and multiplex quantitative PCR reactions were performed with a StepOnePlus PCR System (Applied Biosystems) using the following FAM-labeled TaqMan Gene Expression assays (Applied Biosystems): SP-B Mm00455679_m1, ENac Mm00803386_m1, Aqp5 Mm00437578_m1, SP-C Mm00488144_m1, and Nkx2.1 Mm00447558_m1. The VIC-labeled housekeeping gene, 18S, was used as an internal control. Triplicate ΔΔCT values were generated for each sample. mRNA levels relative to dpc 17 mRNA were calculated by using the equation FC = 2−ΔΔCT. n = 4 for each timepoint; *P-values, calculated by one-way ANOVA with Dunnett post hoc analysis, denote comparisons between indicated values and 17 dpc values; error bars represent SEM.